#uthr

[glitter-stained]

Currently writing an UTRH AU with 17 years old Jason deciding to kidnap the batkids to protect them from Batman, so of course I need a playlist. Does anybody have song recs?

[managermint]

Motley Fool: United Therapeutics Corporation (UTHR) 2019 Q2 Earnings Call Transcript

Motley Fool: United Therapeutics Corporation (UTHR) 2019 Q2 Earnings Call Transcript

Image source: The Motley Fool.

United Therapeutics Corporation (NASDAQ:UTHR) Q2 2019 Earnings Call July 31, 2019, 9:00 a.m. ET

Contents:

Prepared Remarks

Questions and Answers

Call Participants

Trending

Prepared Remarks:

Operator

Good morning, and welcome to the United Therapeutics Corporate second quarter 2019 earnings call. My name is Michelle, and I will be your conference operator today.…

View On WordPress

[managermint]

Motley Fool: Here's Why United Therapeutics Fell 18.1% in May

Motley Fool: Here’s Why United Therapeutics Fell 18.1% in May

What happened

Shares of United Therapeutics (NASDAQ:UTHR) fell more than 18% last month, according to data provided by S&P Global Market Intelligence. The specialty pharmaceutical company reported first-quarter 2019 operating results that showed the business faces persistent headwinds. Revenue declined roughly 7% year over year, while an $800 million up-front payment to Arena Pharmaceuticalsfor…

View On WordPress

[gesforex-blog]

United Therapeutics Corporation – 29.03.2017.

[marketexclusive]

Analyst Activity – Wedbush Reiterates Outperform on United Therapeutics Corporation (NASDAQ:UTHR)

Analyst Activity – Wedbush Reiterates Outperform on United Therapeutics Corporation (NASDAQ:UTHR)

Analyst Ratings For United Therapeutics Corporation (NASDAQ:UTHR) Today, Wedbush reiterated its Outperform rating on United Therapeutics Corporation (NASDAQ:UTHR) with a price target of $229.00. There are 1 sell rating, 6 hold ratings, 5 buy ratings on the stock. The current consensus rating on United Therapeutics Corporation (NASDAQ:UTHR) is Hold (Score: 2.33) with a consensus target price of…

View On WordPress

[breakoutmonitor-blog]

$UTHR – United Therapeutics Corp – Inverse head and shoulders formation breakout United Therapeutics Corp has given positive signal from a inverse head and shoulders formation breakout. Further rise is signaled.

[stockmarketsdaily]

New Post has been published on Stock Markets Daily

New Post has been published on http://www.stockmarketsdaily.com/overvalued-stock-united-therapeutics-corporation-nasdaquthr/14837/

Overvalued Stock: United Therapeutics Corporation (NASDAQ:UTHR)

(adsbygoogle = window.adsbygoogle || []).push();

We look at United Therapeutics Corporation (NASDAQ:UTHR) a company in the Healthcare industry getting a lot of attention at the moment, to assess if it provides value for investors considering buying or selling it. Currently United Therapeutics Corporation is trading at $182.50 after moving down -0.65% in the previous day of trading. [Trend Analysis]

UTHR is trading with a trailing 12 month P/E multiple of 53.99 and an estimated forward P/E multiple of 15.14. The stock has an estimated 5 year annual growth of 19.56% and a PEG multiple of 2.76.

Rather than the usual Price to Earnings (P/E) multiple method, we use a slightly different method to assess if United Therapeutics Corporation is potentially a value buy for investors, the PEG ratio (P/E to growth). This PEG multiple takes into account the expected long term growth in earnings of the company rather than merely the growth for one earnings period ahead as forward P/E does.

That is to say, P/E simply doesn’t account for the long term prospects of UTHR. As a rule of thumb, a stock with a PEG of between 0 and 1 is usually considered to be underpriced, between 1 and 2 to be at fair value and over 2 to be overpriced. Based on the PEG ratio of UTHR being 2.76, we consider United Therapeutics Corporation to likely be overpriced.

This analysis means that value buyers who do not currently hold United Therapeutics Corporation (NASDAQ:UTHR) should not consider buying and investors currently holding the stock should consider selling.

The mean analyst 12 month target price for United Therapeutics Corporation (NASDAQ:UTHR) is currently $169.57 or 7.08% below the current price. Additionally, the stock has been as high as $190.29 and as low as $84.63 in the last 52 weeks. Analysts are estimating that UTHR will report earnings per share of $2.47 next quarter.

[cithaerons]

urthr replied to your post:urthr replied to your post: urthr replied to your... urthr replied to your post:urthr replied to your post: urthr replied to your...

omg I feel so dumb now .__.

oh. aah don’t be sorry! I can’t communicate T^T

nooo don't! ;^; i read that post over again and it did sound really awkward so i apologize. communicating on the internet is weird and difficult PEACE AND LOVE <3